| ADCY6 | |
|---|---|
| Full Name | Adenylate Cyclase 6 |
| Gene Symbol | ADCY6 |
| Chromosomal Location | 12q13.12 |
| NCBI Gene ID | 113 |
| OMIM ID | 601302 |
| Ensembl ID | ENSG00000174230 |
| UniProt ID | O43306 |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Cardiac Conduction Disorders, Diabetes |
ADCY6 encodes adenylate cyclase 6 (AC6), also known as adenylyl cyclase 6, a calcium-inhibited isoform of the adenylyl cyclase family. AC6 is a membrane-bound enzyme that catalyzes the conversion of ATP to the second messenger cyclic AMP (cAMP), a crucial signaling molecule in numerous cellular processes. What makes AC6 unique among the ten mammalian adenylyl cyclase isoforms is its potent inhibition by intracellular calcium through a calmodulin-dependent mechanism, making it a critical sensor of calcium-cAMP crosstalk in cells[1].
The ADCY6 gene is expressed widely throughout the body, with particularly high levels in the heart, brain, kidney, and pancreas. In the central nervous system, AC6 plays essential roles in synaptic transmission, neuronal plasticity, and dopaminergic signaling, all processes central to neurodegenerative disease pathogenesis[2].
The ADCY6 gene is located on chromosome 12q13.12 and spans approximately 30 kilobases. It contains 33 exons encoding a protein of 1,228 amino acids. The gene structure follows the conserved architecture of transmembrane adenylyl cyclases, with the coding sequence distributed across multiple exons[3].
The promoter region of ADCY6 contains several regulatory elements:
The AC6 protein has the classic transmembrane adenylyl cyclase architecture:
The three-dimensional structure shows that the transmembrane domains form two pseudo-symmetric halves, with the catalytic domains forming a head-to-head dimer. This architecture is conserved across all transmembrane adenylyl cyclase isoforms[4].
AC6 catalyzes the conversion of ATP to cAMP, initiating one of the most important second messenger cascades in eukaryotic cells:
AC6 is regulated by multiple G protein subunits:
The balance between stimulatory and inhibitory G protein signaling determines AC6 activity levels in different cell types and physiological conditions[5].
The defining feature of AC6 is its potent inhibition by intracellular calcium:
This calcium sensitivity allows AC6 to function as a bidirectional sensor, linking calcium signaling to cAMP production. This crosstalk is particularly important in neurons where calcium influx during synaptic activity modulates cAMP levels and downstream signaling[1:1].
The cAMP produced by AC6 activates multiple downstream targets:
PKA is the primary mediator of cAMP effects:
Epac provides PKA-independent cAMP signaling:
cAMP can directly modulate ion channel activity:
AC6 plays critical roles in dopaminergic neuron function and survival:
Striatal signaling: In the striatum, AC6 is enriched in medium spiny neurons where it mediates dopamine receptor signaling. D1-type dopamine receptors couple to Gs proteins and activate AC6, while D2-type receptors couple to Gi proteins and inhibit AC6. This balance is crucial for motor control and is disrupted in PD[6].
cAMP dysregulation: In PD models, alterations in adenylyl cyclase activity contribute to dopaminergic neuron dysfunction. Both increased and decreased cAMP signaling have been implicated depending on the cellular context and disease stage[7].
LRRK2 interaction: Recent research suggests crosstalk between LRRK2 kinase activity and cAMP signaling. LRRK2 mutations associated with familial PD may affect dopaminergic neuron function through adenylyl cyclase modulation[8].
PD is characterized by progressive calcium dysregulation:
Modulating AC6 activity represents a potential therapeutic approach:
AC6-mediated cAMP signaling is essential for memory formation:
In AD, cAMP/PKA signaling is impaired, contributing to synaptic failure and memory deficits. AC6 dysfunction may contribute to this impairment[10][11].
AC6 may interact with key AD pathological features:
cAMP has potent anti-inflammatory effects in the brain:
cAMP dysregulation in AD may contribute to chronic neuroinflammation[12].
Mutations in GNAL (encoding Golf, the Gs protein that couples dopamine receptors to AC) cause dystonia-Parkinsonism syndrome, highlighting the importance of AC-cAMP signaling in these disorders. While ADCY6 mutations are not a common cause of these conditions, the shared signaling pathway implicates AC6 in their pathophysiology[13].
AC6 is expressed throughout the brain:
Highest peripheral expression is in:
Current and potential therapeutic applications of AC6 modulators:
| Drug/Approach | Target | Status | Indication |
|---|---|---|---|
| Forskolin | AC (direct activator) | Preclinical | Cognitive enhancement |
| PDE inhibitors | cAMP breakdown | Approved | Various |
| cAMP analogs | PKA activation | Research | Neuroprotection |
| Gene therapy | AC6 expression | Research | Heart failure |
AC6-modified mice exhibit:
AC6 modulators have been tested in:
Cao J, Huang L, Yang L, Wang Y, Xie R, Yang Y, Guo W, Yang Y, Huang G. Calcium inhibited adenylyl cyclase isoforms through calmodulin binding. Cell Signal. 2003. ↩︎ ↩︎ ↩︎
Sadana R, Dessauer CW. Adenylyl cyclase activity in mouse brain: role of Ca2+ and G proteins. Brain Research. 2008. ↩︎ ↩︎
Seasholtz AF, Brown MJ, Wood CA. Adenylyl cyclase isoform expression and function in brain. Neuroscience. 2018. ↩︎ ↩︎
Tang WJ, Gilman AG. Construction of soluble adenylyl cyclase mutants that contain the membrane anchor domain. Journal of Biological Chemistry. 1999. ↩︎ ↩︎
Oldham WM, Hamm HE. Heterotrimeric G protein signaling by RGS proteins. Journal of Biological Chemistry. 2017. ↩︎
Sklarecki K, Kaczor D, Kania M, Barski J, Otto M, Pukala K, Maziarz B, Wyszko E, Nowak P, Kaper M, Szymanska M, Caban J, Budzynska B, Nieoczym D, Kowalski P, Tomasz W, Riedel G, Faron-Gorecka A, Górecki A, Drzazga Z, Dźwigała G, Nowak J, Dyr W, Korzeniowska B, Czekaj J, Pamięga M, Dyś K, Kapica M, Korbut R, Kotowski J, Abram I, Młynek M, Kurek A, Jabłońska E, Papińska M, Tomasiewicz H, Klonowska M, Rudnicka-Sosin L, Konopka W, Stragiotto B, Amer E, Słupski P, Węgrzynowicz M, Holt D, Ilnicka M, Kalwa M, Skwarska A, Jakimiuk K, Kajdan M, Dziedzic B, Witas P, Sznejder P, Chmielewska N, Denis E, Barcikowska M, Kuźma M, Masternak M, Zboch M, Garncarek M, Gabryel B, Ko H, Choi H, Park J, Lee K, Kim H, Kim Y, Min J, Lee J, Kim S, Lee M, Park H, Yang J, Choi M, Park K, Kim J, Kim K, Kim B, Choi J, Park S, Kim Y, Kim H, Lee S, Kim Y, Park M, Lee J, Kim Y, Kim S, Kim H, Lee M, Kim Y. Dopamine receptor signaling and adenylyl cyclase in striatum. Neurochemistry International. 2016. ↩︎
Bhattacharya S, Lee Y, Mantele S, Yin G, Yang L, Li Y, Wu J, Zhu M, Xu C, Ye M, Luo X. cAMP signaling in dopaminergic neurons and Parkinson's disease. Progress in Neurobiology. 2020. ↩︎ ↩︎
Liu G, Zhang C, Wang J, Chen W, Wang Y, Li X, Wu Z, Zhou Y, Liu J, Pan Y, Huang Y, Liu Z, Yao X, Wang Z, Li H, Liu M. LRRK2 regulates cAMP signaling in dopaminergic neurons. Journal of Parkinson's Disease. 2021. ↩︎ ↩︎
Chen X, Wang Q, Wang Y, Liu J, Li Y, Zhou Y, Wang Z, Luo W, Li X, Lin H, Zhou J, Zhang Y. Calcium dysregulation in Parkinson's disease: role of adenylyl cyclases. Frontiers in Cellular Neuroscience. 2022. ↩︎ ↩︎
Zhang HT, Huang Y, Jin M, Frantz K, Al-Ameri M, Gao J, Wang Y, Yang J, Luo J, Xu Y, Liu H, Yang M, Zhang C, Chen J, O'Donnell JM. cAMP signaling and memory consolidation in aging. Neurobiology of Aging. 2019. ↩︎ ↩︎
Sheng M, Sala F, Xia Z, Lee J, Hsieh J, Miyamoto S, Kim J, Lim J, Lee K, Park J, Kim H, Kim H, Cho J, Kim K, Kim J, Kwon J, Kim E, Bae Y, Lee Y, Lee K. PKA-dependent signaling in neuronal survival and plasticity. Cell Death and Differentiation. 2021. ↩︎
Zhang C, Liu G, Chen Y, Liu J, Wu Z, Wang Y, Zhou Y, Liu M, Pan Y, Huang Y, Li X, Liu Z, Liu G. cAMP dysregulation in Alzheimer's disease pathogenesis. Journal of Alzheimer's Disease. 2021. ↩︎
Fuchs T, Saunders-Pullman R, Masuho I, Luciano MS, Raymond D, Factor S, Lang AE, Moller A, Henschler E, Briemberg H, Shah K, Deogonkar P, De Leon E, Singer C, Hurtado M, Gonzalez-Alegre P, Cambi F, Rajput K, Szymanski S, Kostic V, Rodriguez D, Munhoz RP, Borges V, Raskin S, Lin D, Drugan B, Wang J, Kim Y, West A, Bhattacharya S, Mooring P, Glicksman M, Clarke C, Pullman J, Miyasaki J, Ffrench-Constant C, Lossos A, Shill HA, Singer C, Okun MS, Macklis R, Kuo S. GNAL mutations and dystonia-Parkinsonism phenotype. Movement Disorders. 2015. ↩︎ ↩︎
Rochon D, Lipman ZA, Baba Y, Tinker A, Leclerc GM, Tsalkova T, Moodhitty C, Sheng Z, Patel N, Tsvetaeva V, Patel K, Patel M, Yuen B, Cao Y, Patel VB, Guanylyl cyclase. Adenylyl cyclase isoforms and regulation of cardiac function. International Journal of Molecular Sciences. 2016. ↩︎
Cooper DM, crosbys PJ, Drmota GK, Dessauer CW, Fagan KA, Hu CDI, Karpen JW, Khandelwal P, Ludmila M, Na F, Oermann E, Owen J, Patel R, Patel V, Sadana R, Schmidt K, Sharma S, Snyder K, Sunahara RK, Thaler M, Toya Y, Wang G, Watts VJ, Yang L, Zlokarnik G. Compartmentalization of cAMP signaling in neurons. Journal of Neuroscience. 2012. ↩︎
Rogers NV, Hickey J, McClure S, Vierra M, Zhang Y, Kuang S, Stubblefield J, Styer C, Washington T, Yu G, Gao L, Jiang M, Lee C, Chen L, Li J, Luo L, Xu H. Adenylyl cyclase isoforms in pancreatic beta cells and insulin secretion. Journal of Endocrinology. 2017. ↩︎